Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.

@article{Treumer2010SubretinalCO,
  title={Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.},
  author={Felix Treumer and Carsten Klatt and Johann B Roider and Jost Hillenkamp},
  journal={The British journal of ophthalmology},
  year={2010},
  volume={94 1},
  pages={48-53}
}
AIM To evaluate the efficacy and safety of pars plana vitrectomy (ppV) with subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab, and fluid-gas exchange for neovascular age-related macular degeneration (AMD) with submacular haemorrhage (SMH). METHODS Consecutive interventional case series of 12 patients with neovascular AMD with SMH with a maximum history of 14 days. All patients underwent ppV with subretinal coapplication of rtPA and bevacizumab, and… CONTINUE READING